Published in Expert Rev Mol Diagn on July 01, 2009
MicroRNAs as biomarkers in rheumatic diseases. Nat Rev Rheumatol (2010) 1.59
RNA signatures allow rapid identification of pathogens and antibiotic susceptibilities. Proc Natl Acad Sci U S A (2012) 1.23
Improving breast cancer survival analysis through competition-based multidimensional modeling. PLoS Comput Biol (2013) 1.20
Regulation of breast cancer and bone metastasis by microRNAs. Dis Markers (2013) 1.12
Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast. J Breast Cancer (2011) 1.10
Circulating miR-148b and miR-133a as biomarkers for breast cancer detection. Oncotarget (2014) 1.02
MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential. J Zhejiang Univ Sci B (2015) 0.84
Perspective: Does personalized medicine hold the future for medicine? J Pharm Bioallied Sci (2015) 0.82
Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential. BMC Syst Biol (2015) 0.75
Pattern recognition for predictive, preventive, and personalized medicine in cancer. EPMA J (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
Identification of novel genes coding for small expressed RNAs. Science (2001) 44.44
An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science (2001) 44.16
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res (2006) 39.25
Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature (2001) 38.75
miRBase: tools for microRNA genomics. Nucleic Acids Res (2007) 38.61
An extensive class of small RNAs in Caenorhabditis elegans. Science (2001) 34.17
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science (2001) 31.33
MicroRNAs modulate hematopoietic lineage differentiation. Science (2003) 30.05
The microRNA Registry. Nucleic Acids Res (2004) 29.45
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
Principles of microRNA-target recognition. PLoS Biol (2005) 23.70
bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell (2003) 22.14
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature (2007) 21.53
Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev (2003) 17.64
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
Dicer is essential for mouse development. Nat Genet (2003) 15.87
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell (2007) 13.69
miR-21-mediated tumor growth. Oncogene (2006) 9.90
Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell (2005) 9.27
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell (2004) 8.06
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res (2004) 7.96
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 7.86
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res (2008) 7.53
Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem (2007) 7.46
Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol (2004) 7.33
MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem (2007) 6.88
Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res (2007) 6.57
Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science (1985) 6.56
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer (2006) 5.47
Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res (2007) 5.25
How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev (2005) 5.22
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst (2001) 5.09
hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res (2008) 4.84
Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem (2006) 4.59
Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics (2006) 4.57
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem (2008) 4.56
MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene (2008) 4.43
Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol (2007) 4.40
NIH consensus conference. Treatment of early-stage breast cancer. JAMA (1991) 4.35
Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol (2007) 3.93
Retracted MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem (2008) 3.63
The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res (2007) 3.40
The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol (2007) 3.39
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol (2008) 3.23
Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol (2008) 3.18
MicroRNA: implications for cancer. Virchows Arch (2007) 3.17
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol (1990) 3.12
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A (2008) 3.08
Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem (2007) 3.05
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol (2008) 3.02
Radiation therapy for early-stage breast cancer after breast-conserving surgery. N Engl J Med (2009) 2.89
Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther (2008) 2.85
Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res (2006) 2.83
miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res (2008) 2.80
The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer (2005) 2.69
Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res (2009) 2.65
Use of statistics to assess the global burden of breast cancer. Breast J (2006) 2.56
Immunochemical studies of estrogen receptors. J Steroid Biochem (1984) 2.55
microRNA-205 regulates HER3 in human breast cancer. Cancer Res (2009) 2.53
Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol (2008) 2.30
A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res (2008) 2.16
MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res (2006) 2.16
MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol (2009) 2.02
Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res (2005) 2.00
High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat (2008) 1.86
Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res (1997) 1.84
An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples. J Mol Diagn (2008) 1.82
MicroRNA-10b and breast cancer metastasis. Nature (2008) 1.80
Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer (2005) 1.78
National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr (2001) 1.76
MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res (2008) 1.69
Multiple estrogen receptor assays in human breast cancer. Cancer Res (1983) 1.52
Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg (2005) 1.45
Tissues from routine pathology archives are suitable for microRNA analyses by quantitative PCR. J Clin Pathol (2008) 1.44
Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia. Breast J (2006) 1.40
HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol (2007) 1.40
Small inhibitory RNA duplexes for Sp1 mRNA block basal and estrogen-induced gene expression and cell cycle progression in MCF-7 breast cancer cells. J Biol Chem (2002) 1.37
Small is beautiful: microRNAs and breast cancer-where are we now? J Pathol (2008) 1.35
Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res (1977) 1.27
MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev (2009) 1.20
von Hippel-Lindau disease. Lancet (2003) 6.20
Post-analysis follow-up and validation of microarray experiments. Nat Genet (2002) 4.61
Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev (2009) 2.41
Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38
Genome-wide association study in esophageal cancer using GeneChip mapping 10K array. Cancer Res (2005) 2.22
Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res (2007) 2.17
Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet (2013) 2.09
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res (2002) 2.04
Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res (2005) 1.88
2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics (2002) 1.85
Factors in tissue handling and processing that impact RNA obtained from formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem (2008) 1.81
Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst (2006) 1.70
Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. J Am Coll Surg (2010) 1.70
Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery (2007) 1.67
Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer (2002) 1.65
Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab (2009) 1.62
Large-scale profiling of archival lymph nodes reveals pervasive remodeling of the follicular lymphoma methylome. Cancer Res (2009) 1.58
Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications. Proteomics (2003) 1.50
Reoperation for parathyroid adenoma: a contemporary experience. Surgery (2009) 1.50
Partial-volume correction in PET: validation of an iterative postreconstruction method with phantom and patient data. J Nucl Med (2007) 1.49
Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res (2002) 1.39
Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. Biotechniques (2003) 1.36
Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One (2009) 1.33
Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics (2003) 1.33
Parathyroid-specific double knockout of Gq and G11 alpha-subunits leads to a phenotype resembling germline knockout of the extracellular Ca2+ -sensing receptor. Mol Endocrinol (2006) 1.31
Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans. Eur J Nucl Med Mol Imaging (2002) 1.30
Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol Imaging (2003) 1.30
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res (2008) 1.29
Quantitative RT-PCR gene expression analysis of laser microdissected tissue samples. Nat Protoc (2009) 1.27
The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res (2002) 1.26
Successful outcome after surgical management in two cases of the "painful variant" of Hashimoto's thyroiditis. Endocr Pract (2002) 1.25
Tumor vasculature-targeted delivery of tumor necrosis factor-alpha. Cancer (2009) 1.25
Gene expression analysis of esophageal squamous cell carcinoma reveals consistent molecular profiles related to a family history of upper gastrointestinal cancer. Cancer Res (2003) 1.24
SIVQ-aided laser capture microdissection: A tool for high-throughput expression profiling. J Pathol Inform (2011) 1.24
Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Res (2003) 1.22
Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators. Oncogene (2004) 1.22
Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res (2004) 1.21
Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther (2004) 1.21
Development of a clinical decision model for thyroid nodules. BMC Surg (2009) 1.21
Insulinoma: pathophysiology, localization and management. Future Oncol (2010) 1.21
A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer. Oncology (2011) 1.18
Global expression analysis of prostate cancer-associated stroma and epithelia. Diagn Mol Pathol (2007) 1.18
Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica (2011) 1.16
Expression microdissection: operator-independent retrieval of cells for molecular profiling. Diagn Mol Pathol (2004) 1.16
Molecular pathology of the MEN1 gene. Ann N Y Acad Sci (2004) 1.16
Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites. Am J Cancer Res (2011) 1.13
Overexpression of CDC25B and LAMC2 mRNA and protein in esophageal squamous cell carcinomas and premalignant lesions in subjects from a high-risk population in China. Cancer Epidemiol Biomarkers Prev (2008) 1.11
Genome-wide loss of heterozygosity and copy number alteration in esophageal squamous cell carcinoma using the Affymetrix GeneChip Mapping 10 K array. BMC Genomics (2006) 1.09
Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery (2013) 1.09
Malignant insulinoma: spectrum of unusual clinical features. Cancer (2005) 1.07
Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin. Cancer Res (2003) 1.07
Assessment of normalization strategies for quantitative RT-PCR using microdissected tissue samples. Lab Invest (2007) 1.07
Digital slide repositories for publications: lessons learned from the microarray community. Am J Surg Pathol (2011) 1.07
Determination of a minimal deletion interval on chromosome band 8p21 in sporadic prostate cancer. Genes Chromosomes Cancer (2002) 1.07
Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure. J Am Coll Surg (2002) 1.07
Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol (2005) 1.06
A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. Surgery (2005) 1.06
Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol (2011) 1.05
Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res (2008) 1.05
Simplified kinetic analysis of tumor 18F-FDG uptake: a dynamic approach. J Nucl Med (2004) 1.05
Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1. Cancer Res (2009) 1.05
Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis. Int J Cancer (2007) 1.05
Comprehensive characterization of annexin I alterations in esophageal squamous cell carcinoma. Clin Cancer Res (2004) 1.05
Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy. Cancer Res (2008) 1.04
The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin Cancer Res (2003) 1.04
Comparison of snap freezing versus ethanol fixation for gene expression profiling of tissue specimens. J Mol Diagn (2004) 1.04
Antiangiogenic gene therapy of cancer: recent developments. J Transl Med (2004) 1.03
A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res (2008) 1.03
Expression microdissection adapted to commercial laser dissection instruments. Nat Protoc (2011) 1.03
Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. J Vasc Interv Radiol (2011) 1.02
Tumor-associated endothelial cells display GSTP1 and RARbeta2 promoter methylation in human prostate cancer. J Transl Med (2006) 1.02
Immunoguided laser assisted microdissection techniques for DNA methylation analysis of archival tissue specimens. J Mol Diagn (2010) 1.02
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Transl Med (2007) 1.02
Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res (2003) 1.01
Role of metastasectomy in the management of thyroid carcinoma: the NIH experience. J Surg Oncol (2003) 1.01
Microarray gene expression analysis of murine tumor heterogeneity defined by dynamic contrast-enhanced MRI. Mol Imaging (2002) 1.00
Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res (2002) 1.00
Colloidal gold: a novel nanoparticle for targeted cancer therapeutics. Methods Mol Biol (2010) 1.00
Downregulation of Filamin A interacting protein 1-like is associated with promoter methylation and induces an invasive phenotype in ovarian cancer. Mol Cancer Res (2011) 1.00
Molecular imaging of tumor angiogenesis. J Cell Biochem Suppl (2002) 1.00
Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn Mol Pathol (2003) 1.00
Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations. PLoS One (2009) 0.99
Increased matrix metalloproteinase activation in esophageal squamous cell carcinoma. J Transl Med (2010) 0.99
Percutaneous radiofrequency ablation of hepatocellular carcinoma in the presence of portal vein thrombosis. Clin Imaging (2003) 0.99
Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer (2002) 0.99
Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer. BMC Cancer (2014) 0.98